CRISPR Therapeutics AG
CRSP
$56.75
-$3.25-5.42%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.51M | 38.34M | 38.05M | 37.68M | 37.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.51M | 38.34M | 38.05M | 37.68M | 37.31M |
| Cost of Revenue | 498.29M | 443.21M | 420.51M | 437.76M | 430.90M |
| Gross Profit | -494.78M | -404.88M | -382.46M | -400.08M | -393.59M |
| SG&A Expenses | 73.54M | 73.27M | 73.76M | 74.32M | 72.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 571.83M | 516.48M | 494.26M | 512.08M | 503.88M |
| Operating Income | -568.32M | -478.14M | -456.21M | -474.40M | -466.57M |
| Income Before Tax | -577.97M | -484.58M | -463.82M | -381.69M | -362.67M |
| Income Tax Expenses | 3.63M | 3.72M | 3.98M | 3.97M | 3.59M |
| Earnings from Continuing Operations | -581.60 | -488.30 | -467.80 | -385.66 | -366.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -581.60M | -488.30M | -467.80M | -385.66M | -366.25M |
| EBIT | -568.32M | -478.14M | -456.21M | -474.40M | -466.57M |
| EBITDA | -548.84M | -459.48M | -437.25M | -455.24M | -447.31M |
| EPS Basic | -6.51 | -5.58 | -5.42 | -4.52 | -4.36 |
| Normalized Basic EPS | -3.36 | -2.77 | -2.67 | -2.79 | -2.70 |
| EPS Diluted | -6.52 | -5.59 | -5.43 | -4.52 | -4.37 |
| Normalized Diluted EPS | -3.36 | -2.77 | -2.67 | -2.79 | -2.70 |
| Average Basic Shares Outstanding | 359.58M | 349.78M | 343.71M | 341.56M | 337.41M |
| Average Diluted Shares Outstanding | 359.58M | 349.78M | 343.71M | 341.56M | 337.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |